Paratek announces commercial launch of Nuzyra antibiotic in the U.S.

Paratek Pharmaceuticals announced the commercial availability of Nuzyra in the United States. Nuzyra, a modernized tetracycline, is a once-daily intravenous and oral antibiotic for the treatment of adults with community-acquired bacterial pneumonia and acute skin and skin structure infections. Paratek Pharmaceuticals has also partnered with JMI Laboratories to develop a comprehensive initiative called the Keystone that provides access to current antimicrobial surveillance susceptibility data including Nuzyra. Keystone is designed to play an essential role in monitoring the prevalence of antimicrobial resistance in the United States.
https://thefly.com/landingPageNews.php?id=2859511